In this interview, Dr Matthew Roe (AstraZeneca VP, Head of Early Clinical Development) joins us to discuss the results from a study of AZD0780.

The aim of this Phase Ib study was to measure the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD0780, a small molecule oral PCSK9 inhibitor, on top of rosuvastatin treatment on low-density lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidaemia.

Questions
1. What are some of the unmet needs in patients with dyslipidaemia?
2. Can you summarise the mode of action of the study drug?
3. What were the study design, eligibility criteria, and outcome measures?
4. What are the key findings today?
5. What were the safety data?
6. What are the next steps?
8. What are the take-home messages?
9. What is the potential for the combination?

Recorded remotely from Durham, 2024. 

Interviewer: Greg Guillory